Artiam Bio Inc.
Cary, NC
- UEI
- FKJAXBQEDUJ8
- CAGE
- 8N0F0
- Primary NAICS
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Physical address
- 307 Stromer Dr, Cary, NC 27513, USA
- Website
- artiambio.net
- Founded
- 2020
- Employees
- 1-10
- Estimated annual revenue
- $0-$1M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Grant awards
Similar vendors
About the company
Artiam Bio Inc. is a minority-owned, small disadvantaged biotechnology company located in Cary, North Carolina, registered in the System for Award Management (SAM) until February 2026. The company specializes in developing innovative pharmaceutical compounds targeting complex medical conditions, with a strategic focus on developing novel therapeutic interventions for various disorders through advanced receptor-based pharmacological approaches. As a for-profit, Subchapter S Corporation, Artiam Bio Inc. has positioned itself as a research-oriented biotechnology firm committed to advancing medical treatments through preclinical and translational research.
The company has been awarded multiple federal grants from prestigious National Institutes of Health (NIH) institutes, focusing on developing targeted therapeutic compounds for challenging medical conditions. These grants include a $292,279 project from the National Institute on Aging to validate the APT101 compound for treating systemic sclerosis-associated interstitial lung disease, a $368,673 grant from the National Institute on Alcohol Abuse and Alcoholism to develop second-generation partial inverse agonists for alcohol use disorder, a grant from the National Institute on Drug Abuse to develop a treatment for cannabis use disorder, and a project grant from the National Institute of Diabetes and Digestive and Kidney Diseases to identify a peripherally selective neutral antagonist for non-alcoholic steatohepatitis (NASH). Across these projects, Artiam Bio Inc. has demonstrated expertise in developing advanced receptor-based therapeutic strategies, with a particular emphasis on creating compounds that minimize adverse psychiatric effects while maintaining therapeutic efficacy, primarily through innovative approaches to CB1 receptor modulation.
Quick answers
Is Artiam Bio Inc. registered in SAM.gov?
Yes. Artiam Bio Inc.'s SAM.gov registration is active through January 28, 2027.
What is Artiam Bio Inc.'s most recent federal award?
Artiam Bio Inc.'s most recent federal grant award is Validation of APT101 for the treatment of systemic sclerosis-associated interstitial lung disease (SSC-ILD) in an aging… (R41AG090138), from National Institute on Aging (NIH), on September 20, 2025.
On GovTribe
See Artiam Bio Inc.'s full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors